Ginkgo Bioworks (DNA) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Business Growth, Partnerships, and Strategic Direction

• Biopharma is the fastest-growing segment, with over 40 active partnerships, including major companies like Merck, Novo Nordisk, Biogen, and Pfizer.

• Achieved a $9 million milestone payment from Merck and expanded the Novo Nordisk partnership multiple times since 2022, focusing on expression systems and protein discovery.

• Partnerships with Biogen and Pfizer leverage proprietary platforms for advanced drug discovery and RNA construct development.

• Signed deals with leading tech bio and top 10 biopharma companies for new data-driven products.

• R&D partnerships are close, co-development relationships, making it easier to expand deals as technical milestones are met.

Operational Restructuring and Financials

• Reduced annualized cash operating expenses from $500 million to $375 million in 2024, ahead of target, through 30-35% layoffs and site consolidations.

• Closed sites in Europe, New York, and Cambridge, focusing operations on Boston, Emeryville, and Davis.

• Maintained revenue targets despite restructuring, with $120–$140 million in cell engineering services and $50 million+ in biosecurity.

• FY2024 revenue outlook is $215–235 million, with cell engineering and services as primary contributors; biosecurity revenue decreased.

• Ended Q3 with $616 million in cash and no bank debt, aiming to control cash burn and avoid unnecessary fundraising.

Platform Commercialization, Product, and Technology Innovation

• Expanded from R&D partnerships to direct sales of platform tools and services, targeting faster sales cycles and near-term fees.

• Launched Datapoints for functional genomics and antibody developability, offering high-throughput, customizable data generation for AI model training.

• Proprietary automation hardware (RACs) and software (Catalyst ACS) enable scalable, flexible lab operations; Ginkgo Automation offers modular, reconfigurable lab robotics.

• Data generation services support AI/ML model development, with rapid turnaround and customer data ownership.

• Released public datasets and signed pilot deals to accelerate adoption of new offerings.